REPORT ID 6246

EMEA (Europe, Middle East and Africa) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Report 2017

Publish Date
25-Dec-17
Pages
116
Format
Electronic (PDF)

In this report, the EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Commercializing Biomarkers in Therapeutic and Diagnostic Applications for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications market competition by top manufacturers/players, with Commercializing Biomarkers in Therapeutic and Diagnostic Applications sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Roche
    Dako (Agilent Technologies)
    Merck
    BD
    Abbott
    Genesys Biolabs(20/20GeneSystems)
    Affymetrix
    Agendia
    ALMAC
    Arrayit
    Biocartic
    BG Medicine
    Thermo Fisher
    BGI

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Consumables
    Services
    Software

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Oncology
    Cardiology
    Neurology
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Report 2017
1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Overview
    1.1 Product Overview and Scope of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
    1.2 Classification of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
        1.2.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Consumables
        1.2.4 Services
        1.2.5 Software
    1.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market by Application/End Users
        1.3.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Oncology
        1.3.3 Cardiology
        1.3.4 Neurology
        1.3.5 Other
    1.4 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market by Region
        1.4.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Commercializing Biomarkers in Therapeutic and Diagnostic Applications (2012-2022)
        1.5.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2022)

2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Competition by Players/Manufacturers
        2.1.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sale Price by Players (2012-2017)
    2.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume and Value) by Type/Product Category
        2.2.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sale Price by Type (2012-2017)
    2.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume) by Application
    2.4 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume and Value) by Region
        2.4.1 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Price by Region (2012-2017)

3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Value (2012-2017)
        3.1.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2017)
    3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type
    3.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Application
    3.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume by Countries (2012-2017)
        3.4.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2012-2017)
        3.4.3 Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        3.4.4 France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        3.4.5 UK Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        3.4.6 Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        3.4.7 Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)

4 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Value (2012-2017)
        4.1.1 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2017)
    4.2 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type
    4.3 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Application
    4.4 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        4.4.4 Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        4.4.5 UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        4.4.6 Iran Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)

5 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Value (2012-2017)
        5.1.1 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Growth Rate (2012-2017)
    5.2 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Type
    5.3 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Market Share by Application
    5.4 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Volume by Countries (2012-2017)
        5.4.2 Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Countries (2012-2017)
        5.4.3 South Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales and Growth Rate (2012-2017)

6 EMEA Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturers/Players Profiles and Sales Data
    6.1 Roche
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Dako (Agilent Technologies)
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Merck
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 BD
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Abbott
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Genesys Biolabs(20/20GeneSystems)
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Genesys Biolabs(20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Affymetrix
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Agendia
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 ALMAC
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Arrayit
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Biocartic
    6.12 BG Medicine
    6.13 Thermo Fisher
    6.14 BGI

7 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Cost Analysis
    7.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 R